UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 Or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 7, 2018
GB Sciences, Inc.
(Exact name of Registrant as specified in its charter)
|
Delaware
(State or other Jurisdiction of
Incorporation or organization) |
000-55462
(Commission File Number)
|
59-3733133
(IRS Employer I.D. No.)
|
3550 W. Teco Avenue
Las Vegas, Nevada 89118
Phone: (844) 843-2569
(Address, including zip code, and telephone number, including area code, of
registrant's principal executive offices)
N/A
(Former name, former address and former fiscal year, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule l 4a- l 2 under the Exchange Act ( 17 CFR 240. l 4a- l 2)
☐ Pre-commencement communications pursuant to Rule l 4d-2(b) under the Exchange Act (17 CFR 240. l 4d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240. l 3e-4(c))
ITEM 8.01 Other Information Regarding Continuance of Shareholder Meeting.
The special meeting of shareholders noticed to be held at 10:00 a.m. on March 7, 2018, was continued until April 6, 2018, at 10:00 a.m. at the same location being 3550 W. Teco Avenue, Las Vegas, Nevada. John Poss, the CEO of the Company who called the meeting to order stated that the meeting was being continued due to the fact the Company had not received a sufficient number of proxies to constitute a quorum of shareholders to enable the Company to conduct shareholder business. The Company will attempt to solicit additional proxies sufficient to conduct shareholder business on April 6, 2018.
SIGNATURE PAGE
Pursuant to the requirement of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
GB Sciences, Inc.
|
||||
|
Dated: March 9, 2018
|
By:
|
/s/ John Poss
|
||
|
John Poss
|
||||
|
Chief Executive Officer
|
||||